Skip to main content

Nelson Jen An Chao

Donald D. and Elizabeth G. Cooke Cancer Distinguished Research Professor
Medicine, Hematologic Malignancies and Cellular Therapy
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710

Overview


My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome. There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non specific NK cells to prevent relapse. Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies. The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease. The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.

For more information see http://ed-media.mc.duke.edu/BMT.nsf

Current Duke Appointments & Affiliations


Donald D. and Elizabeth G. Cooke Cancer Distinguished Research Professor · 2002 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Professor of Medicine · 2001 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Professor in Integrative Immunobiology · 2001 - Present Integrative Immunobiology, Basic Science Departments
Professor in Pathology · 2011 - Present Pathology, Clinical Science Departments
Research Professor of Global Health · 2018 - Present Duke Global Health Institute, University Institutes and Centers
Member of the Duke Cancer Institute · 1996 - Present Duke Cancer Institute, Institutes and Centers
Chief, Division of Cell Therapy in the Department of Medicine · 2004 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Affiliate of the Duke Regeneration Center · 2021 - Present Duke Regeneration Center, Basic Science Departments

Recent News Items


Published May 17, 2023
More Options for People With Blood Cancer
Published October 15, 2019
Surviving Pediatric Cancer Shouldn't Depend on Where You Live
Published February 9, 2018
How Two Duke Professors Are Giving Families in Tanzania a Better Chance of Beating Cancer

View All News Items

Recent Scholarly Works


New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT.

Journal article Blood · October 2, 2026 The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia ... Full text Link to item Cite

You Are Already Trained for This: The Hematologist/Oncologist's Role in Radiation Mass Casualty Response.

Journal article Blood · September 25, 2026 A large-scale radiation injury or nuclear incident requires an immediate, coordinated medical response that vastly exceeds traditional disaster management frameworks. While specialized networks exist, the initial surge of casualties will inevitably place a ... Full text Link to item Cite

Early Mortality and Conditional Long-Term Survival After Adult Umbilical Cord Blood Transplantation: A 1-Year Landmark Analysis.

Journal article Transplant Cell Ther · August 15, 2026 Umbilical cord blood (UCB) is an established alternative graft source for allogeneic hematopoietic cell transplantation (HCT), but adult use is limited by substantial early morbidity and mortality. Conventional survival estimates from transplantation may o ... Full text Link to item Cite
View All Scholarly Works

Recent Grants


2/3 CTSA K12 Program at Duke University

ResearchMentor · Awarded by National Center for Advancing Translational Sciences · 2025 - 2030

The Gut Microbiome and Development of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Children

ResearchCo-Mentor · Awarded by National Heart, Lung, and Blood Institute · 2025 - 2030

Stimulating Access to Research in Residency (StARR) - NIAID

Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2029

View All Grants

Education


Yale University · 1981 M.D.